Vitru

Vitru FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Vitru (VTRU) as of Oct 21, 2026 is -349.70 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -2,430.01 % — a change of -85.61% (higher).

FCF Conversion

-349.70 %

YoY

-85.61%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vitru is 2023 -349.70 % . FCF Conversion Rate (FCF/EBITDA) of Vitru was 2022 -2,430.01 % . It decreases by -85.61% higher compared to the previous year.

The Vitru FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
225.66 BRL
Jan 1, 2019
146.07 BRL
Jan 1, 2020
-187.72 BRL
Jan 1, 2021
-171.53 BRL
Jan 1, 2022
-2,430.01 BRL
Jan 1, 2023
-349.70 BRL
The Vitru FCF Conversion history
YEARFCF ConversionYoY
-349.70 %-85.61%
-2,430.01 %+1,316.67%
-171.53 %-8.62%
-187.72 %-228.51%
146.07 %-35.27%
225.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitru Stock analysis

What does Vitru do? Vitru Ltd is a British company specializing in the production and sale of high-quality and innovative implants and medical devices. The company was founded in 2011 and is based in London. Its initial focus was on developing products for human body reconstruction, including implants for knees, hips, and shoulders, as well as products for tendon and ligament repair. Vitru produces high-quality products that meet the highest standards by using state-of-the-art technologies and materials. The company has quickly become a leading provider in this market and continues to expand its offerings and expertise. This includes not only the manufacturing of implants but also the development and production of instruments and procedures that enable more precise and efficient surgeries for doctors and surgeons. Vitru also offers products and services in the areas of phenotyping and genotyping, collecting data on a person's genetic characteristics and using that information for personalized medicine and diagnostics. Another business field of Vitru is 3D printing. By utilizing 3D printing technology, the company can rapidly manufacture products and better meet customer needs. Vitru offers a wide range of implants that can be customized to individual customer requirements. In this context, Vitru has also engaged in the production of masks and other facial protection products to contribute to the fight against the COVID-19 pandemic. Vitru's products are known for their high quality, durability, and functionality. They are distributed both in the UK and worldwide and are used in orthopedics, neurosurgery, and other medical specialties. The company has a clear mission to be a global leader in the development and manufacturing of medical devices and implants tailored to the needs of patients and surgeons. To fulfill this mission, Vitru collaborates closely with professionals in the fields of medicine and technology. The company also works closely with hospitals and research institutions to stay up to date with the latest developments in medicine and technology and incorporate them into its products. An example of this is the development of knee implants specifically designed for women to better accommodate their needs. Overall, Vitru has established itself as an important player in the medical technology industry and is committed to improving healthcare for patients worldwide. Vitru is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitru stock

FCF Conversion Rate (FCF/EBITDA) of Vitru is -349.70 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Vitru changed from -2,430.01 % to -349.70 %, representing a -85.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vitru since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vitru with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vitru

All Key Metrics — Vitru